Proceedings of the IASLC international workshop on advances in pulmonary neuroendocrine tumors 2007 Journal Article
| Authors: | Lim, E.; Goldstraw, P.; Nicholson, A. G.; Travis, W. D.; Jett, J. R.; Ferolla, P.; Bomanji, J.; Rusch, V. W.; Asamura, H.; Skogseid, B.; Baudin, E.; Caplin, M.; Kwekkeboom, D.; Brambilla, E.; Crowley, J. |
| Article Title: | Proceedings of the IASLC international workshop on advances in pulmonary neuroendocrine tumors 2007 |
| Abstract: | The International Association for the Study of Lung Cancer, (IASLC) International Congress on Advances in Pulmonary Neuroendocrine Tumors was a two-day meeting held at the Royal Brompton Hospital in London, United Kingdom on the thirteenth and forteenth of December 2007. The meeting was led by 14 member international faculty-in the disciplines of pathology, surgery, medicine, oncology, endocrinology, nuclear medicine, diagnostic imaging, and biostatistics. The aims were twofold, as an educational meeting, and to develop the IASLC International Pulmonary Neuroendocrine Tumors Registry. The meeting highlighted the difference in presentation of the tumors, management options for early and advanced stage disease including the use of novel agents and approaches. The need, process, and approach to an International Registry of Pulmonary Neuroendocrine Tumors were emphasized. International collaboration to develop a retrospective registry, prospective data collection, virtual tissue bank, and collaborative clinical trials were universally agreed as the best way to advance our understanding and treatment of these rare tumors. © 2008 by the International Association for the Study of Lung Cancer. |
| Keywords: | cancer survival; unclassified drug; clinical feature; bevacizumab; cisplatin; doxorubicin; fluorouracil; sunitinib; advanced cancer; drug efficacy; conference paper; alpha interferon; cancer adjuvant therapy; cancer patient; disease free survival; temozolomide; cancer staging; cancer grading; platelet derived growth factor alpha receptor; stem cell factor; unindexed drug; liver toxicity; nephrotoxicity; pain; etoposide; lung non small cell cancer; nausea; vomiting; lung neoplasms; protein p53; neuroendocrine tumor; lung tumor; lung small cell cancer; myelodysplastic syndrome; early cancer; nerve cell adhesion molecule; carcinoma; medical society; granisetron; cancer registry; octreotide; continuing education; inoperable cancer; cytokeratin 14; cytokeratin 5; paraneoplastic syndrome; chromogranin; united kingdom; everolimus; bone marrow toxicity; neuroendocrine tumors; rare disease; bronchus carcinoid; platelet derived growth factor beta receptor; cytokeratin ae1; cytokeratin ae3; streptozocin; hair loss; neuron specific enolase; synaptophysin; large cell neuroendocrine carcinoma; atypical carcinoid; typical carcinoid; pasireotide; large cell neuroendocrine; neuroendocrine tumours; cytokeratin 1; cytokeratin 10; octreotate lu 177; octreotate[3 tyrosine 1,4,7,10 tetraazacyclododecane 1,4,7,10 tetraacetic acid lu 177] |
| Journal Title: | Journal of Thoracic Oncology |
| Volume: | 3 |
| Issue: | 10 |
| ISSN: | 1556-0864 |
| Publisher: | Elsevier Inc. |
| Date Published: | 2008-10-01 |
| Start Page: | 1194 |
| End Page: | 1201 |
| Language: | English |
| DOI: | 10.1097/JTO.0b013e3181861d7b |
| PUBMED: | 18827620 |
| PROVIDER: | scopus |
| DOI/URL: | |
| Notes: | --- - "Cited By (since 1996): 11" - "Export Date: 17 November 2011" - "Source: Scopus" |
Altmetric
Citation Impact
BMJ Impact Analytics
Related MSK Work